Latest From Medivir AB
Farewell established products, hello innovative new drugs! As pricing pressures mount, more multinational companies including Lilly and Roche are switching their business focus in China, looking at product divestments and partnering with local firms.
AbbVie has added Mission Therapeutics to its preclinical partnership roster with a neurology deal to develop DUB inhibitors in Alzheimer’s and Parkinson’s disease.
The key to getting funding for small biotechs which focus on tackling antimicrobial resistance is to get private investors interested to top up 'push' incentives from the likes of CARB-X, the AMR Centre's Peter Jackson tells Scrip.
Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in clinical development.
- Therapeutic Areas
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Medivir AB
- Senior Management
Uli Hacksell, PhD, Pres. & CEO
Magnus Christensen, CFO
Linda Basse, PhD, CMO
Christina Herder, PhD, EVP, Strategic Bus. Dev.
- Contact Info
Phone: (46) 8-5468 31 00
P.O. Box 1086 Huddinge, 141 22
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.